

TECFIDERA (dimethyl fumarate) [preferred] PRIOR AUTHORIZATION FORM

Prior authorization guidelines for Tecfidera are located in the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapters – Multiple Sclerosis Agents and Quantity Limits/Daily Dose Limits accessible at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license #:	
LTC facility contact/phone:		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Medication requested:	<input type="checkbox"/> Tecfidera starter pack (#1 pack = 60 capsules for 30 days, no refills) <input type="checkbox"/> Tecfidera capsule	Strength:	
Directions:	Quantity:	Refills:	
Diagnosis (<i>submit documentation</i>):	Dx code (<i>required</i>):		
Specialty Pharmacy Drug Program: Which specialty pharmacy will be used?		<input type="checkbox"/> Diplomat Specialty Pharmacy <input type="checkbox"/> Walgreen's Specialty Pharmacy	
Initial requests			
1. Does the beneficiary have a diagnosis of a <u>relapsing</u> form of multiple sclerosis?	<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis.</i> <input type="checkbox"/> No – <i>Submit documentation supporting the use of Tecfidera for the beneficiary's diagnosis.</i>		
2. Is Tecfidera being prescribed by a neurologist?	<input type="checkbox"/> Yes <input type="checkbox"/> No – prescriber specialty: _____		
3. Does the beneficiary have results of a complete blood count (CBC) with differential within the 6 months prior to initiating therapy with Tecfidera?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation of lab results.</i>		
Renewal requests			
1. Has the beneficiary experienced improvement or stabilization of the signs and symptoms of multiple sclerosis since starting Tecfidera?	<input type="checkbox"/> Yes <i>Submit documentation of beneficiary's response to therapy.</i> <input type="checkbox"/> No		
2. Does the beneficiary have results of a complete blood count (CBC) with differential 6 months after starting Tecfidera and annually thereafter?	<input type="checkbox"/> Yes <i>Submit documentation of lab results.</i> <input type="checkbox"/> No		

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
------------------------------	--------------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.